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Abstract 
The AGO2 protein is part of a highly conserved family of RNA-binding protein called 
Argonaute. This protein family plays a key role in gene expression regulation in association 
with different classes of small non-coding RNA (miRNA, siRNA, piRNA). In addition to the 
post-transcriptional regulation in the cytoplasm, AGO2 protein acts also in the nucleus at the 
transcriptional level with a mechanism, in humans, not clearly identified. To elucidate the 
molecular functions of AGO2 in human cells, we performed an extensive analysis of both 
proteins and small RNAs associated to endogenous AGO2 protein by high-throughput 
technologies. We identified various AGO2-interactors not previously described. Interactors 
that can shed light on molecular functions exerted by AGO2 in novel as well in known 
biological processes. In particular, we provided several evidence regarding the mechanism of 
AGO2-mediated transcriptional regulation. Interestingly, we uncovered the interaction of 
AGO2 with the SWI/SNF chromatin remodeling complexes. The SWI/SNF is a multisubunit 
complex that alter the structure or the positioning of nucleosomes, thus modulating the access 
of regulatory proteins and transcription factors to DNA. Futhermore, we identified a new class 
of AGO2-associated small RNAs in the nucleus that showed a remarkable overlap with the 
binding sites of SWI/SNF complexes, regulatory regions in proximity of transcription start 
site and with chromatin marks associated with transcriptional active state. Taken together, our 
data suggests that nuclear AGO2 regulates the transcriptional initiation interacting with 
SWI/SNF complexes to ensure proper nucleosome positioning in proximity of promoter 
regions. 
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Introduction 
The Argonaute protein family 
Argonaute proteins constitute a highly conserved protein family whose members have a key 
role in gene-expression regulation pathways in association of small RNAs. Small RNAs such 
as short interfering RNAs (siRNAs), microRNAs (miRNAs) or Piwi-interacting RNAs 
(piRNAs) are anchored into specific binding pockets and guide Argonaute proteins to target 
RNA molecules for translational inhibition or degradation. In particular, a mainly factor that 
dictates the specific mechanism of silencing mediated by Argonaute proteins is the degree of 
complementarity between the small RNA and the RNA target. In details, a perfect 
complementary determines the endonucleolytic cleavage of RNA target, a process known as 
slicing. On the contrary, translational inhibition and mRNA destabilization are induced when 
a partial complementarity occurs.  
The number of Argonaute proteins is highly variable between species, ranging from one in 
S. pombe to 27 in C.elegans. In mammals have been identified eight Argonaute proteins 
(Höck J, 2008). Based on sequence similarities, the Argonaute protein family can be divided 
phylogenetically into three subfamilies (Farazi TA, 2008). The largest subfamily comprises 
the AGOs, named after its founding member AGO1 in A. thaliana. The second subfamily 
comprises the Piwis, named after the D. melanogaster protein PIWI (P-element induced 
wimpy testis). The third subfamily, Class 3, consists exclusively of C. elegans proteins. The 
AGO proteins are ubiquitously expressed and bind to siRNAs or miRNAs, whereas the PIWI 
proteins are mostly restricted to the germ line and associate with piRNAs. 
Characteristic structural feautures 
Argonaute proteins are multidomain proteins that contain an N-terminal domain, and a PAZ, 
middle (MID) and PIWI domain (Fig.1a). The recent determination of the crystal structure of 
full-length human AGO2, consistent with previous studies of prokaryotic homologues, have 
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revealed a bilobate architecture, with the MID and PIWI domains forming one lobe, and the 
N-terminal and PAZ domains constituting the other (Fig.1b) (Schirle NT, 2012).  
The interaction between small RNAs and AGOs occurs through several contact points on the 
protein, mediated by distinct domains. In particular, the small RNA 5’ and 3’ termini are 
recognized by the PAZ and MID domains, respectively. Once loaded the small RNA, 
Argonaute proteins silence RNA targets by slicing, activity that resides in the PIWI domain. 
The PAZ domain contains a specific binding pocket that anchors the characteristic two 
nucleotides 3’ overhang. Although there are no sequence-specific contacts, the base of the 
terminal nucleotide stacks against the aromatic ring of a conserved phenylalanine residue 
(Yan KS, 2003). 
The MID domain contains a highly basic pocket, which specifically binds the characteristic 
5’ phosphate of small RNAs and anchors the small RNA onto Argonaute proteins (Ma JB, 
2005). The MID domain has been implicated in protein-protein interactions (Till S, 2007) 
and, based on sequence similarities to the 7-methylguanine (m7G) cap-binding motif of 
eukaryotic translational initiation factor 4E (eIF4E), also in the binding of the m7G cap of 
target mRNA (Kiriakidou M, 2007). 
The PIWI domain shows extensive homology to RNase H, an endoribonuclease that cleaves 
RNA–DNA hybrids (Parker JS, 2004a). Indeed, biochemical in vitro studies of Argonaute 
proteins from several model organisms have shown that some are endonucleases, and these 
are often referred to as ‘slicers’. In vitro assays using RNA substrates complementary to 
exogenous siRNA (Liu J, 2004) as well as endogenous miRNAs (Meister G, 2004) have 
identified AGO2 as the only member of the human AGO subfamily with endonuclease 
activity. Moreover, based on mutation studies, the catalytic triad of human AGO2 has been 
characterized as D(597), D(669) and H(807) (Song JJ, 2004). Interestingly, human AGO3 is 
catalytic inactive even though the catalytic triad DDH is conserved. This indicates that other 
factors such as post-translational modifications or interactions with specific proteins may 
modify the activity of AGO proteins. 
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Figure 1 Structure of human AGO2. (A) Schematic of the AGO2 primary sequence. (B) Front and top views of Ago2 with 
the N (purple), PAZ (navy), MID (green), and PIWI (gray) domains and linkers L1 (teal) and L2 (blue). A generic guide 
RNA (red) can be traced for nucleotides 1 to 8 and 21 (Schirle NT, 2012). 
 
Subcellular localization of AGO proteins 
AGO proteins (AGOs) have been implicated in both post-transcriptional and transcriptional 
gene-expression regulation. This dual level of regulation reflects the localization of AGOs 
both in the cytoplasm and in the nucleus. The distinct subcellular localization of AGO 
proteins is mediated by accessory proteins and post-tradutional modifications, which co-
ordinate AGOs activity with the plethora of cellular signals. 
In the cytoplasm AGO proteins are enriched in distinct foci such as P-bodies and stress-
granules. The former are cellular sites where occur mRNA turnover and storage (Eulalio A, 
2007a), the latter are structures induced upon cellular stress and contain mRNAs stalled in the 
process of translation initiation (Leung AK, 2006 ). It has been reported that the AGO2 P-
body localization is mediated by several accessory proteins such as GW182 (Eulalio A, 
2007b), and influenced by post-tradutional modifications such as phosphorilation at serine-
387 (Zeng Y, 2008).  
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The funding of AGO proteins in the nucleus of human cell is recent (Robb GB, 2005), and 
alternative nuclear trafficking mechanism are reported. Emerging evidence shows that the 
cytoplasmic and nuclear AGO functions are co-ordinated by a common set of proteins. Imp8, 
that is required for binding of AGO proteins to a variety of mRNA targets in the cytoplasm, 
modulates nuclear localization of AGO2 as well (Weinmann L, 2009). Similarly, TNRC6A, 
that interacts with AGOs and triggers translational repression and/or mRNA degradation in P-
bodies, translocates AGO2 in and out the nucleus via its own recently discovered nuclear 
localization signals (NLS) and nuclear export signals (NES) (Nishi K, 2013). 
Functions of AGO proteins 
AGO-associated small noncoding RNAs. AGO proteins exert their regulatory activity in 
association with small noncoding RNA molecules that fall into two main classes: siRNAs and 
miRNAs. 
The first class, siRNAs, derives from long double-stranded RNA (dsRNA) molecules that 
result from RNA virus replication, convergent transcription of cellular genes or mobile 
genetic elements, self-annealing transcripts or experimental transfection (Ghildiyal M, 2009). 
The endonuclease Dicer functions as a molecular ruler to cleave the dsRNA at ~21–25-
nucleotide intervals. After Dicer-mediated cleavage, one strand of the siRNA duplex (the 
guide strand) is loaded onto an AGO protein that is the core component of the RNA-induced 
silencing complex (RISC). AGO loading takes place in the RISC-loading complex, a ternary 
complex that consists of an AGO protein, Dicer and a dsRNA-binding protein (known as 
TRBP in humans). During loading, the non-guide (passenger) strand is cleaved and ejected. 
AGO complexes uses the guide siRNA to associate with target RNAs containing perfectly 
complementary sequence and then catalyses the slicing of these targets. After slicing, the 
cleaved target RNA is released, and the RISC is recycled for another round of slicing (Zamore 
PD, 2000). 
miRNAs, the second class, are encoded in the genome. These small RNAs are transcribed 
by polymerase II from endogenous miRNA genes resulting in a primary transcripts (pri-
miRNAs) that contain ~65–70-nucleotide stem–loop structures. The hairpin structure is 
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excised in the nucleus by the Drosha–DGCR8 complex to yield a precursor miRNA (pre-
miRNA). After its export to the cytoplasm, the pre-miRNA undergoes another 
endonucleolytic cleavage, which is catalyzed by Dicer, generating a miRNA–miRNA* duplex 
of ~21–25 nucleotides (where miRNA is the guide strand and miRNA* is the passenger 
strand). For most miRNAs, only one strand accumulates as mature miRNA. Such asymmetric 
loading is guided by the relative thermodynamic stability of the 5’ ends of the small RNA 
duplex. The strand whose 5’ end is less stably paired is preferentially incorporated into AGO 
complexes, whilst the passenger strand is subsequently degraded (Bartel DP, 2009).  
In addition to this canonical miRNA biogenesis pathway, some alternative miRNA biogenesis 
pathways have recently been discovered. For example, the mirtron subclass is encoded in the 
introns of genes and is generated directly from byproducts of intron splicing and disbranching 
events (Berezikov E, 2007). 
miRNAs generally interact with their mRNA targets through a limited base-pairing of only 
2-7 nt (seed region) at the 5’end. With few exceptions, miRNAs-binding sites lie in the 
3’UTR and are usually present in multiple copies. Typically, mRNA may have several 
putative targets for both the same and different miRNAs, and any particular miRNA may have 
hundreds of putative mRNA targets. Hence, given the substantial number of miRNAs, there 
exists a staggering combinatorial network of miRNA-mediated gene regulation (Selbach M, 
2008). 
Post-transcriptional regulation. The mechanism by which a small RNA regulates its mRNA 
target reflects both the specific AGO protein association and the extent of complementarity 
between the small RNA and the mRNA. In general, a fully complementary to their mRNA 
targets, typical of siRNAs, directs endonucleolytic cleavage of the mRNA, whereas a non 
perfect complementarity, characteristic of miRNAs, induces translation repression and mRNA 
degradation.  
The mechanism by which AGO proteins mediate translational repression is still a matter of 
debate. Indeed, multiple mechanisms acting on translation initiation (Meister G, 2007), 
translation elongation (Petersen CP, 2006) and on the degradation of nascent polypeptides 
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(Nottrott S, 2006) are reported. Intriguingly, recent data suggests that the nuclear 
transcriptional history of an mRNA influences whether a miRNA represses its translation at 
the initiation or the elongation step (Kong YW, 2008). 
Degradation of mRNAs associated to AGO-miRNA complexes involves deadenylation 
(removal of the poly(A) tail) (Eulalio A, 2007c), and/or decapping (removal of the m
7
G cap 
structure) (Rehwinkel J, 2005). The exposure of mRNA termini led to exonucleolytic 
digestion from the 5’ and 3’ends by the action of the exosome and of the exonuclease XRN1, 
respectively (Parker R, 2004b). 
miRNAs might also silence their targets by sequestering mRNAs into P-bodies, which 
exclude the translation machinery, and releasing them upon specific signals allowing the re-
enter into polyribosomes fraction for translation (Bhattacharyya SN, 2006). 
Although miRNAs have long been thought to act by down-regulating protein synthesis, 
recent reports indicate that they can also stimulate translation under certain conditions 
(Vasudevan S, 2007). Thus, translational regulation by miRNAs would oscillates between 
repression and activation during the cell cycle: in proliferating cells they repress translation, 
whereas in G1/G0 arrest they mediate activation (Vasudevan S, 2007). 
Transcriptional regulation. In addition to their post-transcriptional role in the cytoplasm, 
AGO proteins also function in the nucleus either repressing or activating transcription 
(Gagnon KT, 2012). In humans, the existence of nuclear RNAi pathways was first inferred 
from observations that nuclear miRNAs and siRNAs could cause cleavage of RNA targets, 
such as 7SK small nuclear RNA (Robb GB, 2005). In addition, endogenous human AGO2 
was identified in the nucleus with highly specific antibodies (Rudel S, 2008). 
The first report of human transcriptional gene silencing (TGS) utilized exogenous siRNAs 
to silence expression of an integrated GFP reporter driven by the eukaryotic translation 
elongation factor alpha (EF1α) promoter (Morris KV, 2004). The silencing at transcriptional 
level was confirmed by nuclear run-on analysis, which is the gold standard for differentiating 
silencing effects mediated by TGS from those of the post-transcriptional pathways. 
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Subsequently, other reports described the silencing of various genes, including E cadherin, 
RASSF1, TGFb receptor II, progesterone receptor, major vault protein, androgen receptor, 
cyclooxygenase-2, CDH1, and c-myc (Ting AH, 2005) (Castanotto D, 2005) (Janowski BA, 
2007) (Kim JW, 2007) (Napoli S, 2009) (Green VA, 2011). 
Mechanistic details about TGS have begun to emerge after the observation that siRNA-
induced silencing at the EF1α promoter was sensitive to the Pol II inhibitor α-amanitin 
(Weinberg MS, 2006). This observation led to the proposal of two models to explain the 
mechanism of TGS: (a) the siRNA binds to DNA, facilitated by the opening of the DNA 
duplex by the transcription machinery; (b) the siRNA binds to nascent promoter-associated 
RNA. Work by Han et al. favored the latter by revealing a requirement for a promoter-
associated transcript (Han J, 2007). The antisense strand of the siRNA was shown to target a 
EF1α promoter-associated RNA variant with an extended 5’UTR. In addition, the association 
was inhibited by RNase A but resistant to RNase H treatment, implicating an RNA-RNA 
interaction in TGS.  
Other studies have also demonstrated a requirement for promoter-associated transcripts for 
small RNA-mediated gene silencing. Some of these studies have shown that, similar to EF1α, 
silencing requires sense strand transcripts (Hawkins PG, 2009), while others have found that 
antisense transcription through the targeted region is necessary (Schwartz JC, 2008). 
The findings reported to date, support a model for TGS in which AGO-small RNAs 
complexes are guided to their targets by complementary base-pairing with low copy, 
promoter-associated Pol II transcript. This serves as a scaffold for the recruitment of 
chromatin-modifying complexes that favor heterochromatin formation and, therefore, 
decrease transcription of the targeted gene. 
More recently, small RNA-targeting of sequences beyond the mRNA 3’terminus of the PGR 
gene has been demonstrated to induce TGS (Yue X, 2010). Targeting genomic regions outside 
promoter sequence involves a looping mechanism bringing the 3’ terminus and the promoter 
into close proximity to allow modulation of promoter activity. 
The report of transcriptional gene activation (TGA) showed increase expression of E-
cadherin, p21, and VEGF on the transfection of promoter-targeting siRNAs into cultured cells 
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(Li LC, 2006). The mechanism by which transcriptional activation is achieved shares 
common features with the transcriptional silencing. The transcriptional opposite outcome 
depends on the specific region targeted by the small RNA and by the different set of 
modifying complexes recruited. 
Emerging evidence has revealed that the TGA/TGS in human cells can be mediated not only 
by exogenous small RNA but also by endogenous ones. Consistently, it has been reported that 
a substantial fraction of human miRNAs are present in the nucleus, with even an abundance 
greater than their cytoplasmic levels, and, in some cases, shown to alter promoter activity. 
Cases such as miR-373 and miR-320 in which the former induces and the latter represses 
transcription (Place RF, 2008) (Kim DH, 2008). Moreover, it has been recently discovered 
endo-siRNAs also in mammals with a putative role in transcriptional regulation (Yang N, 
2006). Many are the genomic sources of dsRNA triggers for endo-siRNA such as: structured 
loci that pair intramolecularly to produce long dsRNA, complementary overlapping 
transcripts and bidirectionally transcribed loci, protein-coding genes that associate with the 
cognate pseudogenes and from regions of pseudogenes that form inverted repeated structures 
(Ghildiyal M, 2009). 
 
SWI/SNF chromatin remodeler complexes 
In eukaryotic cells, genetic information encoded in over 1 meter of DNA is packaged into 
chromatin and compartmentalized in the nucleus. The basic unit of chromatin is the 
nucleosome, which consists of 146 base pairs of duplex DNA wrapped around a histone 
octamer comprised of two of each of the conventional histone proteins: H2A, H2B, H3 and 
H4. Highly related histone variants are also incorporated throughout the genome for 
regulatory purposes (Talbert PB, 2010). A fifth histone protein, H1, promotes higher order 
chromatin structures by encouraging condensation of neighboring nucleosomes from “beads 
on a string” to the 30 nm fiber. As this resulting fiber accounts for only ~25-fold of a 5000-
fold DNA-to-nucleus compaction ratio, several other as yet unknown mechanisms must 
contribute to higher order compaction and nuclear organization. 
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Despite this intricate packaging, DNA must be accessible for critical cellular processes such 
as transcription, replication, recombination, and repair. DNA accessibility is facilitated by two 
classes of enzymes, ATP-dependent nucleosome remodelers and histone modifying enzymes, 
which work in concert to direct nucleosome dynamics. In this way, chromatin organization 
provides a packing solution and an opportunity for gene expression regulation. 
Histone modifying enzymes modify the N-terminal tails of histone proteins (by acetylation, 
methylation, phosphorylation and ubiquitylation) to alter the structure of chromatin and 
provide binding sites for regulatory proteins. In fact, many chromatin-associated proteins 
contain domains that bind histone modifications such as the bromodomain that recognizes 
acetylated residues. 
Chromatin remodeling complexes utilize the energy of ATP to disrupt nucleosome-DNA 
contacts, move nucleosomes along DNA, and remove or insert histone octamers. They thus 
make DNA/chromatin available to proteins that need to access DNA or histones directly 
during cellular processes. These enzymes play an essential role in several aspects of 
embryonic development including pluripotency, cardiac development, dendritic 
morphogenesis and self-renewal of neural stem cells. In the adult, deletion or mutation of 
these proteins often leads to tumorigenesis as a consequence of a dysregulated cell cycle 
control (Weissman B, 2009) 
The best-studied family of chromatin remodeler is the evolutionarily conserved SWI/SNF 
family (Clapier CR, 2009). The human SWI/SNF complexes are large multi-subunit 
complexes approximately of 2MDa in size that use the energy of ATP hydrolysis to remodeler 
nucleosome. These complexes consist at least of 9-12 subunits including one of two mutually 
exclusive catalytic ATPase subunits (BRG1 and BRM); a set of highly conserved core 
subunits (SNF5, BAF155 and BAF170); and accessory subunits that are thought to contribute 
to the targeting, assembly and regulation of lineage-specific functions of the complexes. The 
combinatorial assembly of accessory subunits, some of which have multiple isoforms, enables 
multiple varieties of SWI/SNF complexes to exist both within a given cell and across cell 
types (Wu JI, 2009).  
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In mammals cells, the SWI/SNF family can be divided into BAF and PBAF subfamily. This 
subdivision is due to the exclusive presence of ARID1a-b only in BAF complexes and 
BAF180, BAF200, and BRD7 in PBAF complexes (Fig.2). These exclusive subunits provide 
functional specificity recruiting the complexes to specific loci and the association with 
specific proteins (Nie Z, 2000) (Thompson M, 2009).  
 
 
 
Figure 2 SWI/SNF complexes subfamilies. The human SWI/SNF complexes are divided into two subfamilies BAF and 
PBAF in base of exclusive subunits ARID1 (blue) and BAF 180 (red), respectively. Invariants proteins of the SWI/SNF 
complexes (core and ATPase subunits) are reported in green, whereas accessory proteins are shown in light brown (Wilson 
BG, 2011). 
 
 
The multiple assembly of the subunits reflects the pleiotropic functions of the SWI/SNF 
complexes that range from DNA replication (Cohen SM, 2010), DNA repair (Osley MA, 
2007) to gene expression regulation (Urnov FD, 2001).  
To exert this multiplicity of roles, SWI/SNF complexes have to first contact specific genomic 
region either directly, contacting DNA and histone modifications, or indirectly by protein-
protein interactions. 
The direct recruitment is mediated by DNA binding domains (HMG-like and AT-rich 
interactive) and by domains that recognize specific histone modifications, such as acetylation 
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(bromodomains) and methylation (chromodomains), present in several complexes’ subunits. 
Indeed, the SWI/SNF complexes are defined polymorphic readers of epigenetic modifications 
(Wu JI, 2009). Moreover, their large size (about 12-fold bigger than a nucleosome) should 
enable reading of multiple histone modifications on adjacent nucleosomes providing 
significant affinity for either targeting and retention. 
Conversely, the indirect recruitment involves protein-protein interaction with histone 
modifying complexes (Zhang HS, 2000) and with transcriptional activators and repressors 
such as p53 (Lee D, 2002), cyclin E (Shanahan F, 1999), nuclear hormone receptors (Trotter 
KW, 2008). 
One of primary functions of SWI/SNF complexes is to assist in gene regulation. A genome-
wide analysis of SWI/SNF binding sites indicates that SWI/SNF complexes likely contribute 
to gene regulation through many different avenues. In fact SWI/SNF complexes are reported 
to bind promoters, enhancers, CTCF sites and many regions occupied by Pol II (Euskirchen 
GM, 2011). Furthermore, SWI/SNF complexes may facilitate looping interactions among 
these various elements. It has been shown in vitro that SWI/SNF can interact simultaneously 
with multiple DNA sites and generate loops between them (Bazett-Jones DP, 1999). 
So, once targeted to specific promoters or enhancers, SWI/SNF complexes promote transition 
to and from the active and repressed chromatin state. These opposite effects are mediated by 
interactions with different types of coregulators. For example, SWI/SNF complexes interact 
with MYC, a transcription factor that regulate gene expression programmes during cell cycle 
progression, apoptosis and differentiation. In particular, the core subunit SNF5 directly 
interacts with MYC and is capable of cooperating in the activation of MYC target genes in 
vitro (Cheng SW, 1999). By contrast, the ATPase subunits BRG1 binds to RB and facilitates 
the repression of RB target genes, including E2Fs and CCND1 (Trouche D, 1997). 
Transcriptional activation by SWI/SNF complexes is achieved by sliding or ejecting 
nucleosome allowing the transient exposure of binding sites for transcriptional activators and 
the stabilization of pre-initiation complex formation (Salma N, 2004). Additionally, SWI/SNF 
have been shown to be associated with regions downstream the promoter and to influence the 
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RNA Pol II promoter escape (Soutoglou E, 2002) and transcription elongation (Corey LL, 
2003). 
On the contrary, SWI/SNF repress transcription inducing a more compact chromatin 
conformation, and also allowing transcriptional repressors to bind to chromatin or facilitating 
other modifications of the chromatin such as deacetylation of histones. 
Besides the role in transcriptional regulation, recent findings illustrate that SWI/SNF act 
also posttranscriptionally regulating not only the amount of mRNA synthesized from a given 
promoter but also the type of alternative transcript produced. SWI/SNF interact with 
components of the nascent pre-mRNP complex and with the transcription machinery (Cho H, 
1998). These interactions cause a delay in the transcription elongation rate, which in turn 
affects splice site selection. Moreover, SWI/SNF associate with several components of the 
spliceosome and with Sam 68, an ERK-activated enhancer of variant exon inclusion (Batsché 
E, 2006). The posttranscriptional regulation of SWI/SNF seems to be independent from its 
chromatin remodeling activity. In fact, mutation of the ATPase domain of hBrm did not 
impair its effect on splicing regulation (Batsché E, 2006).  
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Aim of the Thesis 
Studies over the past years have provided strong evidence regarding the multi-level regulation 
of gene expression operated by AGO proteins. In particular, human AGO2 protein, the only 
AGO endonucleolytically active, has been demonstrated to act either post-transcriptionally or 
at transcriptional level. It is likely that this multiplicity of roles is exerted by (a) the 
association with specific proteins that would modulate AGO2 activity in response to 
determined cellular cues, and target AGO2 to different cell compartments and to different 
protein complexes; (b) the small RNA loaded into AGO2 protein which confers specificity to 
AGO2 complexes for the RNA molecule to be targeted. 
In order to elucidate the diversified roles of AGO2, we aimed at the characterization of both 
proteins and small RNAs associated to AGO2 protein by high-throughput technologies.  
To provide more physiological results compare to previous studies effectuated in 
overexpression conditions, a monoclonal antibody against the endogenous human AGO2 
protein was utilized.  
From this extensive analysis, we will be able to provide further insights into known AGO2 
functions and to identify new biological processes in which AGO2 is involved. 
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Experimental Procedures 
Cell culture 
HeLa S3 cells were grown in DMEM (Gibco) supplemented with 10% fetal bovine serum 
(Sigma), L-glutamine (Gibco) and penicillin-streptomycin (Gibco). 
For the SILAC (stable isotope labeling by amino acids in cell culture) analyses, HeLa S3 cells 
were grown, in SILAC DMEM (PAA) supplemented with 10% dialyzed fetal bovine serum 
(PAA), nonessential amino acids L-glutamine and L-leucine (Sigma), penicillin/streptomycin, 
and either a) “light” amino acids, L-lysine and L-arginine (SIGMA) or b) “heavy” isotope 
labeled amino acids, L-lysine-
13
C6, 
15
N2-HCl (Sigma-Aldrich/Isotec) and L-arginine-
13
C6, 
15
N4-HCl (Sigma-Aldrich/Isotec). The cells were adapted for at least six generations to 
achieve complete incorporation of the isotope labeled amino acids before they were 
propagated to a scale needed for the experiment. 
Extracts preparation 
For total cell extract, cells were washed and scraped off the culture plates with PBS, then 
lysed in appropriates volumes (20x10
6
 cells/ml) of IP-buffer (150 mM KCl; 25 mM NaCl; 2 
mM EDTA; 0.5% NP40; 0.5 mM DTT; protease inhibitor (Sigma)) and incubated on ice for 
20 min. After that, the lysate was cleared for 10 min at 16,000 g. 
Cytosolic and nuclear extracts were prepared as following: cells were resuspended, firstly, in 
two volumes of ice-cold buffer I (0.3 M sucrose in 60 mM KCl; 15 mM NaCl; 5 mM MgCl2; 
0.1 mM EGTA; 15 mM Tris-HCl pH 7.5; 0.5 mM DTT; protease inhibitors), then added other 
two volumes of ice-cold Buffer II (Buffer I with 0.4% NP-40) (25x10
6
 cells/ml final), mixed 
gently, and placed on ice for 10 min. Afterwards, cell lysate was layered on 24 ml of a sucrose 
cushion (1.2 M sucrose in 60 mM KCl; 15 mM NaCl; 5 mM MgCl2; 0.1 mM EGTA; 15 mM 
Tris-HCl pH 7.5; 0.5 mM DTT) and centrifuged in a pre-chilled swing-out rotor at 10,000 g 
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for 20 minutes at 4°C. The cytoplasmic fraction was removed, cell nuclei were lysed in IP-
buffer (20x10
6
 cells/ml) and cleared. The nuclear and cytosolic fractionation efficiency was 
evaluated by western blotting analysis. H1 and GAPDH proteins were used as controls of the 
nuclear and cytosolic fraction, respectively. 
Western blotting analysis 
Proteins were resolved on 6 or 10% SDS-PAGE gels and transferred to protran nitrocellulose 
membrane (Whatman) by semi-dry blotting. Blots were blocked with 5 or 10% nonfat dry 
milk in PBST, depending on the antibody that was subsequently used. Specific proteins were 
detected by using SuperSignal West Pico Chemiluminescent reagents (Thermo Scientific). 
The following antibodies were used: anti-AGO2 (clone 11A9 Ascenion); anti-BAFF155 
(Abcam); anti-BRG1 (Abcam); anti-GAPDH (Cell Signaling); anti-H1 (Millipore); anti-
tubulina (Sigma), goat-anti mouse and anti-rabbit IgG-HRP conjugated (Bio-Rad); anti-rat 
IgG-HRP conjugated (Jackson). 
Chromatin binding assay 
The chromatin binding assay was performed as described previously (Cernilogar FM, 2011). 
Briefly, 10x10
6
 HeLa S3 cells were washed with cold PBS. 1x10
6
 cells (control fraction, C) 
were resuspended in RIPA buffer (150 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% DOC, 
0.1% SDS, 1% NP-40, Protease inhibitors) and left for 30 min. on ice. The remaining cells 
were lysed for 15 min on ice in cold CSKI buffer (10 mM PIPES, pH 6.8, 100 mM NaCl, 1 
mM EDTA, 300 mM sucrose, 1 mM MgCl2, 1 mM DTT, 0.5% Triton X-100, Protease 
inhibitors). The cell lysate was divided into two portions, which were centrifuged at 500 g at 
4 °C for 3 min. The supernatants (S1 fraction) contain Triton-soluble proteins. One of the 
pellets was washed twice in CSKI buffer and then resuspended in RIPA buffer (the P1 
fraction). The second pellet, after washing in CSKI buffer, was resuspended in CSKII buffer 
(10 mM PIPES, pH 6.8, 50 mM NaCl, 300 mM sucrose, 6 mM MgCl2, 1 mM DTT, protease 
inhibitors), then treated with DNase I (Roche) for 30 min. at 25°C and extracted with 250 mM 
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NH2SO4 for 10 min at 25 °C. The sample treated with DNase and salt was then centrifuged at 
1,200 g for 6 min. at 4 °C, and the supernatant (S2 fraction) and the pellet (P2 fraction) were 
collected. The P2 fraction was also resuspended in RIPA buffer. The equivalent of 1x10
6
 cells 
of all fractions were analyzed by western blotting. 
Immunoprecipitations 
SILAC experiments. Light and Heavy total-cell lysates were pre-cleared with Protein G-
sepharose beads (Sigma) for 2 hr 4°C under constant rotation and then filtered 0.45 µm filter 
(Millipore). Concurrently, anti-AGO2 (clone 11A9 Ascenion) and anti-rat IgG (Sigma) 
antibodies were coupled to Protein-G-sepharose beads for 2 hr at 4°C. After that, protein 
concentration was determined using Bradford reagent (Bio-Rad) and equal amounts of 
proteins from Heavy and Light lysates were used for the subsequent immunoprecipitation 
(IP). An aliquot of total extracts was taken out (input). In a first experiment, from the Heavy 
lysate was conducted the specific IP for AGO2 protein whereas from the Light lysate was 
performed the control IP with nonspecific rat IgG. In a second experiment, the pairing of 
lysates and antibodies was swapped. After overnight (o.n.) IP, the beads were washed once 
with IP-buffer for 5 min., next three times with IP-wash buffer (50 mM Tris-HCl, pH 7.5; 300 
mM NaCl; 5 mM MgCl2; and 0.05% Nonidet P-40). An aliquot of each IP was taken out to 
control the immunoprecipitation efficiency by western blotting. At this moment, Heavy IP 
and Light IP were mixed together and processed as a single sample throughout the following 
elution step. The beads were equilibrated in elution buffer (300 mM NaCl, 50 mM Tris-HCl 
pH 8, 0.01% NP-40, 5 mM MgCl2) and the proteins immunoprecipitated were eluted from the 
antibody matrix by competition with synthetic AGO2 peptide (GeneScript) in about 50 µl of 
elution buffer for 1 h at 22°C 750 rpm for two times. The eluate was collected, cleaned up 
from eventually remaining beads with Micro Bio-Spin Chromatography Columns (BIO-RAD) 
and subjected to mass spectrometry analysis. 
Co-immunoprecipitations experiments. Whole-cell lysate (about 30x10
6
 cells) or nuclear 
fraction of HeLa S3 cells (about 80x10
6
 cells) were incubated o.n. at 4°C under constant 
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rotation with antibodies pre-coupled beads (anti-AGO2; anti-rat IgG; anti-BAF155 (Abcam); 
anti-mouse IgG (Sigma)). All IP samples were washed once with IP-buffer for 5 min. and 
three times with IP-wash buffer. SDS-PAGE sample buffer (Sigma) was added to the beads 
and the co-immunoprecipitated proteins boiled for 5 min. and analyzed by western blotting.  
For the analysis of RNA-dependent interactions, two approaches were utilized. In the first, 
AGO2-IP and the control IgG-IP were equally distributed into two tubes and 50 µl of PBS 
containing 100 µg/ml RNAse A (Sigma) were added to one tube, whereas only PBS to the 
other tube. After incubation at 4°C for 1 hr, beads were denaturated by adding protein sample 
buffer. In the second approach, RNase was added directly at the co-immunoprecipitation step. 
An aliquot of the lysate (input) and IP with or whitout RNAse A were taken out and RNA 
extracted by TriReagent (Sigma) according to the manufacturer’s protocol. The RNA 
degradation efficiency was evaluated by agarose gel electrophoresis and by RT-qPCR 
analysis of miR-21, miR-16 and GAPDH mRNA. 
RNA Immunoprecipitation experiments (RIP). The purified nuclei of about 200x10
6
 HeLa 
S3 cells were lysated in IP-buffer supplemented with RNase inhibitors (Promega) and 
centrifugated at 16,000g at 4°C. Next, the nuclear lysate was pre-cleared by adding Protein G-
sepharose beads for 2 hr 4°C under constant rotation and then filtered through 0.45 µm filter. 
Lysate aliquots were taken out for RNA and protein inputs.  
Antibodies anti-AGO2 and anti-rat IgG were coupled to protein G sepharose beads for 2 h at 
4°C in IP-buffer containing 1 mg/ml heparin (Sigma). Coupled sepharose beads were washed 
with IP-buffer and subsequently incubated with the pre-cleared nuclear lysate o.n. at 4°C. 
Immunoprecipitates were washed ones with IP-buffer 5 min. 4°C, and three times with IP-
wash buffer 5 min. 4°C. After the final wash, the beads were reconstituted with IP wash 
buffer and an aliquot was taken out for western blot. The input sample and IPs were firstly 
treated with DNaseI-RNase-free 10 min. at 37°C, secondly proteinase K digested (Roche). 
Total RNA and co-precipitated RNA was extracted by phenol:chloroform:isopropyl alcohol 
and precipitated in ethanol at -80°C. The efficiency of nuclear-AGO2 immunopurified RNAs 
was controlled by qRT-PCR of miR-21 and miR-16.  
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RNA samples were send to a facility company for libraries preparation and sequencing. 
Sequencing was performed on Illumina platform. 
qRT-PCR 
RNA was reverse-transcribed with enhanced AMV reverse transcriptase (Sigma) using 
specific primers. Subsequently, cDNA was used as template for qPCR performed with iCycler 
(Bio-Rad) using SensiMix SYBR & Fluorescein (Bioline) according to the manufacturer’s 
instructions. All real-time experiments were performed in triplicate. Data were normalized 
relative to measured levels of U4 small nuclear RNA.  
Bioinformatics analysis on RNA-seq data 
The adaptor sequences, attached during short library construction, were removed from the raw 
data. Afterwards, we evaluated the reads quality using FastQC. The reads were filtered out for 
microRNAs, tRNAs, rRNAs and other known non-coding sRNAs by mapping against 
miRBase (version 18) database and hand-cured non-coding database using Bowtie (Langmead 
B, 2009). The resulting filtered sequences were aligned to the hg19 assembly version of 
human genome. Alignment parameters were to restrict to perfectly matching reads in at least 
first 18 bases. Only the reads that map uniquely on the human genome were further analyzed. 
The reads were clustered by merging into a single cluster reads that map on the same strand of 
the genome with at least 1 nt of overlap After that, the genomic coordinates corresponding to 
the clusters were intersected with the genomic coordinates of the selected features generated 
from the ENCODE project (Affymetrix ENCODE Transcriptome project, 2009). The selected 
features were reported in Tab.1. In order to examine the significance of our data, for each of 
the selected genomic features a shuffle file was produced. The shuffle file was generated by 
repositioning the genomic coordinates of the feature randomly on the same chromosome. 
Next, the overlap ratio between our data with real (m value) and shuffled (n value) genomic 
features was computed. A ratio m/n <1 indicates a casual overlapping between our sequences 
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with the selected genomic features. A ratio m/n >1 suggests a likely correlation. Clustering 
and genomic intersections were performed using dedicate BedTools (version 2.14.2).  
 
 
 
Table 1 Selected genomic features. The genomic features are divided into structural and associated to chromatin, active 
(euchromatin) and inactive (heterochromatin). 
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Results 
Proteomic characterization of AGO2-associated proteins 
As part of our efforts to characterize AGO2 complexes, we investigated the AGO2-associated 
proteins by SILAC/MS approach. The SILAC is a metabolic labeling strategy that uses stable 
isotope labeled amino acids in growth medium to encode cellular proteomes for quantitative 
analysis. To this end, HeLa S3 cells were grown in media containing the “light” amino acid or 
its isotopically labeled (“heavy”) analogue. From the total lysate of “heavy” cells we 
immunopurified the endogenous AGO2 protein using a monoclonal antibody. As control, a 
parallel immunoprecipitation with aspecific IgG was performed on the “light” cells. 
Moreover, a swapping between antibodies and SILAC labeled cells was conducted. 
The two biological replicas were concordant and provided us the identification of several 
known and novel AGO2-associated proteins. In Tab2 is reported the top list of co-purified 
proteins of one experiment. The proteins were ranked on the enrichment value of the specific 
immunoprecipitation over the control one. 
As expected, we identified some of the proteins previously shown to associate with AGO2 
which result implicated in transcriptional regulation and mRNA destabilization. Among the 
most enriched we found TNRC6A-B-C, MOV10, HuR, the subunit 1 of CCR4-NOT 
deadelynation complex and PABP. We identified other members of AGO subfamily (AGO1-
AGO3) and several heterogeneous nuclear ribonucleoproteins, ribosomal proteins, RNA 
helicases. 
Moreover, from our proteomic analysis emerged several nuclear proteins that were not known 
to be associated to AGO2. 
With the aim to uncover if AGO2 associates with proteins that are part of specific 
macromolecular complexes or are involved in same pathways, we performed a Gene 
Ontology analysis using GOrilla tool. The ranked list of AGO2-associated proteins were 
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given as input to GOrilla with default running parameters. The output for cellular components 
category is reported in Fig.3 as a directed acyclic graph (DAG).  
The analysis revealed various macromolecular complexes many of which are involved in 
the well-known post-transcriptional role of AGO2. Besides the cytoplasmatic complexes, 
from the analysis emerged with high significance nuclear complexes implicated in mRNA 
processing (mRNA cleavage and polyadenylation) and in chromatin remodeling. Intriguingly, 
our results revealed the association of AGO2 to the main family of chromatin remodeling 
complexes: the SWI/SNF family. Among the most highly enriched proteins in our AGO2-
immunoprecipitations we found all the core proteins (BAF155, BAF170, SNF5), both the 
ATPase subunits (BRG1 and BRM) and several accessory proteins including the subunits 
signature of BAF (ARID1a-b) and PBAF complexes (BAF180). As results, our quantitative 
MS analysis suggests that AGO2 is broadly associated to several SWI/SNF complexes.  
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Table 2 SILAC/MS results. Top-list of AGO2-associated proteins ranked on fold enrichment over the control 
immunoprecipitation. 
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Validation of AGO2-SWI/SNF complexes interaction 
As the nuclear proteins emerged from the proteomic analysis were particularly interesting, 
consistent with evidence on the AGO2 role in transcriptional regulation, we focalized our 
study on AGO2-nuclear complexes. In particular, we proceeded to investigate the interaction 
between AGO2 and SWI/SNF chromatin remodeler complexes. 
Figure 3 GO terms analysis (cellular component category) of AGO2-associated proteins. The resulting 
enriched GO terms are visualized using a DAG graphical representation with color coding reflecting their 
degree of enrichment. 
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To confirm that AGO2 and SWI/SNF associate in vivo, immunoprecipitations and western 
blotting experiments on HeLa S3 cells were carried out. We immunoprecipitated AGO2 
protein from whole cell extracts of unlabeled HeLa S3 and by western blotting verified the 
interaction with BAF155 (a core protein) and BRG1 (one of the two mutually exclusives 
ATPase) (Fig.4A). Moreover, we performed the reverse immunoprecipitation using antibody 
anti-BAF155 (Fig.4B). As shown in Fig.4A, both BAF155 and BRG1 co-immunoprecipitate 
specifically with AGO2 protein and, in a specular manner, AGO2 co-immunoprecipitates with 
the core subunits of SWI/SNF complexes. 
 
Figure 4 Human AGO2 interacts with SWI/SNF subunits BAF155 and BRG1. (A) HeLa S3 whole cell extracts were 
immunoprecipitated using anti-AGO2 or IgG (negative control) and analyzed by western blotting using antibodies anti-
BAF155 (core subunits) and anti-BRG1 (one mutually exclusive ATPase). (B) Reverse co-immunoprecipitation using 
BAF155 antibody was blotted with anti-AGO2. 
 
AGO2 is known to exert its multiple functions in union with both small and long RNA 
molecules. Therefore, to examine whether the AGO2-SWI/SNF complexes interaction was 
RNA dependent, we performed RNase A treatments on immunoprecipitates.  
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As shown in Fig.5A, the interaction of BAF155 and BRG1 with AGO2 was not impaired 
upon RNAse A treatment. Therefore, we demonstrated that the association is independent of 
RNA molecules and that involves a protein-protein interaction. 
 
 
Figure 5 AGO2-SWI/SNF complexes interaction is RNA independent. In the experiment reported, AGO2-
coimmunoprecipitates from HeLa S3 whole cell extracts were treated or not with RNase A and the association with 
BAFF155 and BRG1 were evaluated by western blotting.  
 
SWI/SNF complexes interact specifically with AGO2 and not with AGO1 
In several reports it has been demonstrated a role for AGO1 in transcriptional regulation (Kim 
DH, 2006). Moreover, in our proteomic analysis AGO1 was found associated with AGO2. 
Hence, to investigate if AGO1 interacts with SWI/SNF complexes too, we carried out the co-
immunoprecipitation experiments using both AGO1 and BAF155 antibody (Fig.6). Neither 
immunoprecitating for AGO1 (Fig.6A) nor for BAFF155 (Fig.6B) it was possible to observe 
an interaction between these proteins.  
Thus, our result suggests that only AGO2 specifically interacts with SWI/SNF complexes. 
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Figure 6 AGO1 does not interact with the SWI/SNF complexes. The interaction between AGO1 and BAF155 was tested 
by direct (A) and reverse (B) co-immunoprecipitation experiments in HeLa S3 cells followed by western blotting analysis. 
 
AGO2 interacts with SWI/SNF complexes in the nucleus 
SWI/SNF complexes have predominantly a nuclear localization in virtue of their activity in 
chromatin remodeling. In addition, AGO2 nuclear localization has been reported (Rüdel S, 
2008). Hence, reasoning about a plausible concerted mechanism of action between AGO2 and 
SWI/SNF complexes it was necessary to confirm such interaction in the nucleus, besides the 
validations performed on whole cells extracts. To this aim, we performed a cell fractionation 
into cytosolic and nuclear fraction, followed by AGO2 immunoprecipiation from the nuclear 
fraction. The association with BAF155 was verified by western blot (Fig.7B). The purity of 
our cytosolic and nuclear fractions was determined by immunoblot analysis, as shows Fig.7A, 
the cytoplasmic marker GAPDH and the nuclear marker H1 were appropriately partitioned 
into cytosolic and nuclear fractions, respectively.  
As shown in Fig.7B, our results confirm the interaction between AGO2 and BAF155 in the 
nucleus of HeLa S3 cells. 
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Figure 7 AGO2 and SWI/SNF complexes interact in the nucleus. (A) Control of cell fractionation by blotting for GAPDH 
and H1, cytosol and nuclear marker respectively. (B) AGO2-BAF155 co-immunoprecipitation from the nuclear fraction of 
HeLa S3 cells. 
Characterization of AGO2-SWI/SNF complexes interaction in the nucleus 
To evaluate the presence of AGO2 in different nuclear compartments, we carried out a 
chromatin fractionation experiments. This fractionation also known as chromatin-binding 
assay was adapted to HeLa S3 from Cernilogar FM et al. (Cernilogar FM, 2011) and the 
experimental scheme reported in Fig.8A. Briefly, this fractionation protocol rely on the 
separation of the chromatin-bound proteins (P1) from proteins that are not bound to chromatin 
(S1) in base on solubility to TritonX-100 of S1 fraction proteins. The chromatin-bound 
proteins are instead released only after high salt and DNase treatment (S2). The efficiency of 
the fractionation was assessed by the specific distribution of Tubulin, a chromatin unbound 
marker, and H1, a chromatin-bound marker (Fig.8B).  
The AGO2 and BAF155 distribution profiles through the several resulting fractions were 
compared (Fig.8B). As expected, AGO2 was mainly detected in the S1 fraction, that includes 
the cytosolic and nucleoplasmic components, respect to BAF155. Interestingly, a substantial 
amount of AGO2 was revealed also in S2 fraction that specifically represents protein 
associated to chromatin as well as BAF155. 
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Given that we demonstrated the interaction of AGO2 with SWI/SNF also in nucleus and 
identified AGO2 in the chromatin fraction, we suggests that the AGO2 and SWI/SNF 
complexes may co-operate at chromatin level. 
 
 
Figure 8 Chromatin binding assay. (A) Scheme of the procedure used to fractionate HeLa S3 cells (Cernilogar FM, 2011). 
Chromatin associated proteins should be found in fractions P1 and S2. (B) Equal amounts of each resulting fraction was 
analyzed by western blotting for the presence of the indicated proteins. Tubulin (TUB) serves as a chromatin unbound 
marker, whereas H1 is a chromatin bound marker that is fully released only after high salt and DNase treatment. 
 
Analysis of nuclear AGO2-associated small RNA 
The interaction of AGO2 with SWI/SNF complexes prompted us to hypothesize a concerted 
role of AGO2 and SWI/SNF in chromatin dynamics and possibly in gene expression 
regulation. 
The current model for gene expression regulation exerted by AGO2 indicates that AGO2 
utilizes small RNAs to recognize target molecules. 
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Therefore, in order to elucidate the mechanism through which AGO2 can bind to chromatin 
and recognize specific loci, we performed the analysis of small RNAs bound to nuclear 
AGO2 by RNA-seq.  
To address this issue, we immunopurified the AGO2-bound small RNAs from the nuclear 
fraction of HeLa S3 cells. As control, a parallel immunoprecipitation using aspecific rat IgG 
was performed. RNAs extracted from the total nuclear RNA sample (Input) and from the IPs 
samples were subjected to deep-sequencing. Two independent biological replicas were 
effectuated. 
The analysis and interpretation of the huge amount of data obtained from the deep-
sequencing required the setup of a bioinformatic pipeline. The first step of our bioinformatic 
analysis was annotation of the reads. The reads were first aligned against miRBase and 
against a manually cured non-coding RNA database, in order to identify those reads which 
map to RNAs which are already known to be bound by AGO2 (miRNAs, few tRNA) as well 
as common contaminants (e.g. rRNAs). The sequences which could not be mapped to any of 
the above mentioned RNA classes were aligned to human genome. The percentages of 
different classes of non-coding sRNAs observed in the Input, in the AGO2-IP and IgG-IP 
samples are depicted in Fig.9. 
.. 
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Figure 9 RNA-seq data annotation. The Pie charts illustrate the RNA classes present in the Input, AGO2-IP and IgG-IP 
samples. miRNA (microRNAs); tRNA (transfer RNAs); rRNA (ribosomal RNAs); Rfam (non-coding sRNAs present in 
Rfam database); MuM (multiple matching sequences); other sRNA (uncharacterized non-coding sRNAs); unmapped (reads 
no mapping on the human genome). 
 
Only those reads mapping to a single locus were further analyzed, while Multiple Matching 
reads (MuM) were not investigated. However, no significant enrichment in MuM reads was 
observed in AGO2 sample compared to Input and IgG, ruling out the possibility that nuclear 
AGO2 preferentially binds repetitive sequences. 
In the Input sample, the most abundant classes of RNAs were those of tRNA and rRNA 
followed by miRNA class. The less abundant were multiple matching and Rfam sequences. 
The IgG annotation profile was similar to the Input indicating that the immunoprecipitation 
procedure per se had no bias for a particular class of RNAs. On the contrary, the main class of 
RNA in the AGO2 sample was represented by that of miRNA. This specific miRNAs 
enrichment underlines the efficiency of our AGO2 immunoprecipitation, as miRNAs 
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constitute the principal class of non-coding RNA associated to AGO proteins. Moreover, from 
the reads annotation, in all samples emerged a class of low abundance, uniquely mapping 
sequences not included in any non-coding RNA databases. These sequences are reported in 
the pie chart as “other” RNAs. 
Since endo-siRNAs have been discovered also in mammalian cells (Yang N, 2006) and 
mechanistic details about their function is lacking, we aimed at the discovery of new 
uncharactherized sRNA associated to AGO2. For this reason, we proceeded to investigate the 
“other” RNAs.  
To evaluate whether these “other” RNAs may have a functional role or are purely 
background noise, a size analysis was performed (Fig.10). The size range considered was 
from 18 to 50 nt, where 18 is the minimum length required for alignment and 50 is the 
sequencing length.  
 
 
 
Figure 10 Size distribution of the uncharacterized RNAs (other RNA). Number of reads of “other” RNAs present in 
AGO2-IPed RNAs, Input and IgG-IPed RNAs were plotted in base to the size range. 
The “other” RNAs of the Input and IgG samples showed a homogenous distribution in the 
considered range. On the contrary, the AGO2-IPed “other” RNAs displayed a size peak of 22-
23 nt. Interestingly, this observed size represents the canonical length of small RNAs bound 
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to AGO proteins. This result led us to exclude the hypothesis of degradation products or 
aspecific materials, and corroborates the idea of a novel class of RNA associated to AGO2.  
We wondered whether these “other” RNAs would be putative miRNAs. Therefore, we 
performed a mirRNA discovery analysis using miRanalyzer, but with negative results. This 
indicates that “other” RNAs represent an uncharacterized class of non-coding sRNAs 
associated to AGO2. 
In light of this finding, we proceeded to analyze how the newly identified sRNA class was 
distributed along the genome. For each sample, overlapping reads on the same strand of the 
human genome were grouped together in a cluster. Based on an arbitrary value of 100 
reads/cluster, clusters were divided into HIGH copy (>100 reads) and LOW copy (<100 
reads).  
 
 
 
Figure 11 Reads clustering. (A) Clusters were divided into HIGH and LOW copy on the arbitrary value of 100 
reads/cluster. (B) LOW clusters were subdivided into intergenic, sense and antisense. Sense and antisense distinction was in 
base on the reads orientation respect to an annotated transcript. Intergenic clusters mapped on region without any annotated 
transcript. 
 
As evidenced from the schematic representation reported in Fig.11A, the HIGH and LOW 
clusters showed a different profile. The LOW clusters presented few reads covering a wider 
region of the genome. The HIGH clusters were characterized by numerous stacked reads with 
a relatively uniform 5’ terminus, similar to a miRNAs cluster. We hypothesized that reads that 
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form HIGH clusters may be putative miRNA sequences not predicted by miRanalyzer 
algorithms. For this reason, we focused our analysis exclusively on the LOW clusters. 
LOW clusters were divided into sense, antisense and intergenic (Fig.11B). Respectively 
sense and antisense clusters map on the same and on the opposite strand of an annotated 
transcript (ENSEMBL). Intergenic clusters map in regions without any annotated transcript.  
Afterwards, we aimed at obtaining details about the genomic regions on which the new class 
of AGO2-associated RNAs map. With this intent, the genomic coordinates of clusters (sense, 
antisense and intergenic) of each sample (Input, AGO2-IP and IgG-IP) were intersected with 
the genomic coordinates of selected features (Tab.1), and the number of reads overlapping the 
features was calculated (m value). As we were interested in the transcriptional role of AGO2, 
besides structural features, were also chosen features associated with an active (euchromatin) 
and silenced (heterochromatin) transcriptional state of chromatin. Moreover, to test the 
significance of the observed overlap, the intersection of the genomic coordinates was 
effectuated also with shuffled features, thus obtaining the number of reads overlapping control 
shuffled features (n value). A overlap ratio (m/n) <1 indicates an overlap equal or lower than 
the one expected choosing random sequences, whilst a ratio m/n >1 is suggestive of a likely 
correlation. Even more importantly, the overlap ratios obtained for AGO2 sample were 
compared to those obtained for input and IgG samples. A comparable overlap ratio in the 
AGO2 and Input sample, even in the case of ratios > 1, would suggest that the observed 
overlap is the result of some experimental bias and not specific for AGO2-bound RNAs. 
 
Collectively, the analysis showed that intergenic and to a lesser extent antisense RNAs 
associated to AGO2 mapped on euchromatin, regulatory regions in proximity of TSS 
(transcriptional start site). Some overlaps investigated between the intergenic clusters with 
euchromatin-associated features are reported in Fig.12. Input, AGO-IP and IgG-IP samples 
were plotted for each genomic feature in base to the overlap ratio.  
Intriguingly, we observed a strong enrichment in AGO2 sample for sRNA corresponding to 
BAF155 and BRG1 binding sites. In addition, we found a considerable enrichment for 
binding regions of proteins implicated in transcription initiation like TBP protein (TATA 
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binding protein). We observed a remarkable enrichment for CpG islands, strong promoter, 
strong enhancers, for different histone modifications correlated with transcriptional activation 
near the TSS like H3K9ac.  
 
 
 
Figure 12 Overlap between Intergenic clusters with euchromatin-associated features. Input, AGO2-IP and IgG-IP 
samples were plotted for each reported features based on the overlap ratio.  
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By contrast, no significant correlation (overlap ratio minor than one) was observed for 
heterochromatin-associated features. In Fig.13 are reported the overlap ratios of intergenic 
clusters for the histone modification H3K27me3 which is associated with Polycomb-repressed 
regions (Simon JA, 2009) (Fig.13).  
Regarding the analysis of the sense clusters, we observed a significant enrichment only for 
the structural features of 3’UTR (data not shown).  
 
 
 
 
 
Figure 13 Overlap between intergenic clusters with 
heterochromatin-associated features. Input, AGO2-IP and 
IgG-IP samples were plotted for the heterochromatin-associated 
feature H3K27me3 based on the overlap ratio. 
 
 
 
 
 
Since the new class of AGO2-associated small RNAs preferentially localizes on promoter 
regions, we were interested in examining their distribution at TSS level. Consistent with the 
AGO2-SWI/SNF interaction, we focused this analysis on promoters regulated by BAF155 
using ChIP-seq data of Euskirchen GM. et al. (Euskirchen GM, 2011). For this analysis, all 
LOW clusters reads of AGO2-IP sample mapping on BAF155-bound promoters were 
considered. The reads were subdivided into sense and antisense relative to the direction of 
gene transcription. As can be seen in Fig.14, AGO2-associated RNAs surround the TSSs with 
a divergent orientations. The sense AGO2-bound RNAs (blue profile) mapped downstream of 
the TSSs, overlapping genic transcripts and peaking in abundance between +0 and +50 
nucleotides downstream of the TSSs. The antisense AGO2-bound RNAs mapped upstream of 
the TSSs peaking between nucleotides -100 and -300 nucleotides. 
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Figure 13 Alignment reads to BAF155 promoters. Low clusters reads of AGO2-IP sample were mapped on promoters 
presenting BAF155 binding sites and divided into sense (blue profile) and antisense (red profile) relative to direction of gene 
transcription. 
 
Taken together, we identified a new class of non-coding RNAs associated to AGO2 in the 
nucleus which mapped to regulatory euchromatin regions implicated in the regulation of 
transcriptional initiation. Intriguingly, consistent with the identification of AGO2-SWI/SNF 
interaction, we observed a considerable enrichment for sRNAs corresponding to binding sites 
for two core components of SWI/SNF complexes. Moreover, the AGO2-associated sRNAs 
presented a bidirectional distribution surrounding the TSSs of promoters regulated by 
BAF155. 
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Discussion 
A significant number of studies have revealed the key role of AGO2 in gene expression 
regulation. In fact, AGO2 has recently been demonstrated to regulate gene expression at the 
transcriptional level as well as post-transcriptionally in association with small RNAs which 
mediate the recognition of target molecules (Gagnon KT, 2012). 
To shed light on the multiplicity of roles exerted by AGO2, we have performed an extensive 
analysis of both proteins and small RNAs associated to AGO2 protein by high-throughput 
technologies. In order to obtain a more physiological scenario on biological processes 
regulated by AGO2, compared to previous studies carried out in overexpression condition, we 
have immunopurified AGO2 using a monoclonal antibody against the endogenous AGO2 
protein in a human cell line. 
Collectively, our broad analysis provides an important contribution to understanding the 
molecular functions exerted by AGO2 both in new and known biological processes, for 
example, the modulation of RISC assembly and activity with endosomal trafficking (Lee YS, 
2009). In this regard, we have identified the heterotrimer VPS35-VPS26-VPS29 (data 
reported in table 2) implicated in cargo recognition of the retromer complex. This complex 
plays a central role in the retrieval of different cargo proteins from the endosome to the trans-
Golgi network. The exploration of this interaction will provide insights into the dynamics of 
RISC assembly and introduces the possibility of crosstalk or direct regulation between the 
RISC complex with pathways regulated by the retromer complex, including those controlling 
growth factors signalling, intracellular infection and intercellular transport. 
Moreover, our results suggest that AGO2 is implicated also in different processes in the 
nucleus, in addition to those previously described, such as mRNA processing and chromatin 
remodelling.  
In particular, we have provided several evidence regarding the mechanism through which 
AGO2 regulates the gene expression at the transcription level. To date, the mechanisms of 
AGO2-mediated transcriptional regulation has not been clearly elucidated. 
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Notably, we have demonstrated that nuclear AGO2 interacts via protein-protein association 
with SWI/SNF complexes which are the main family of chromatin remodeler. The SWI/SNF 
complexes play a fundamental role in transcription regulation mainly by altering the structure 
and the positioning of nucleosomes, thereby modulating the access of regulatory proteins to 
DNA (Saha A, 2006). Moreover, we have identified a novel class of AGO2-associated small 
RNAs in the nucleus that map to euchromatin regions implicated in the regulation of 
transcriptional initiation (e.g. CpG islands, promoters, enhancers) and that shows a 
remarkable overlap with the binding sites of SWI/SNF complexes. It is reasonable to suppose 
that these small RNAs would be operative in directing the recruitment of AGO2 in association 
with SWI/SNF complexes to chromatin. 
Several models have been proposed regarding the modality of AGO2-binding on specific 
loci. One of the most intriguing postulates an RNA-RNA interaction between the AGO2-
bound sRNA and a non-coding or coding RNAs spanning through the promoter region (Han J, 
2007). The characterization of AGO2-bound long RNAs in the nucleus by RIP (RNA-
immunoprecipitation) and the identification of the binding sites on RNA molecules by PAR-
CLIP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation) 
experiments, will enable to verify the model of AGO2 chromatin recruitment via RNA-RNA 
interaction. 
Taken together, our data suggests that nuclear AGO2 regulates the transcriptional initiation 
interacting with SWI/SNF complexes to ensure proper nucleosome positioning in proximity 
of promoter regions. We propose to test this hypothesis in further experiments, for example 
by genome-wide nucleosome positioning in control cells and in cells in which AGO2 has 
been knocked down. Moreover, the analysis of the genomic loci bound by AGO2, through 
ChIP-AGO2 experiments, along with the identification of RNAs associated to SWI-SNF 
complexes might provide further details. 
The SWI/SNF complexes show pleiotropic functions, which are conferred by the 
combinatorial assembly of several accessory subunits. Since we have observed that AGO2 is 
associated to several SWI/SNF complexes, we hypothesize that AGO2 would cooperate with 
SWI/SNF also in other biological processes. The recent report in Drosophila about the 
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involvement of AGO2 in DNA damage repair (Wei W, 2012) as well as the established role 
of SWI/SNF in the same pathway (Osley MA, 2007) are suggestive of a their concerted 
activity in this context, too.  
Furthermore, our results raise many future issues. The first concerns the biogenesis 
mechanism of this new class of sRNAs associated to AGO2. Many would be the mechanisms 
underlying their generation, among which we hypothesize the divergent transcription. It has 
been reported that the most active genes, in organism as diverse as yeast and mammals, are 
bidirectionally transcribed and that this might have a regulatory function in transcription 
(Seila AC, 2009). Recent studies in mammals have shown that polymerase occupancy is 
nearly equivalent in both directions (Core LJ, 2008) and that the polymerase upstream and 
antisense to the directions of genes does not productively elongate after the site of pausing 
(Seila AC, 2008). Moreover, high-throughput analysis of the small RNA population from 
mouse ES cells (Seila AC, 2008) and from human fibroblasts (Core LJ, 2008) have identified 
a high density of RNA mapping in proximity of the TSS. These promoter-proximal small 
RNAs overlap the regions bound by the sense and antisense paused RNA polymerases 
suggesting that at least some might be by-products of so called “paused” RNAPII. The 
bidirectional distribution of our AGO2-associated small RNAs around the TSS of promoters 
bound by BAF155 would be consistent with the scenario above mentioned.  
Another question, regarding the generation of the various promoter-proximal sRNA, is 
whether a DICER processing would be involved similar to endo-siRNAs identified in mouse 
oocytes (Watanabe T, 2008). The analysis of our new class of nuclear AGO2-associated 
RNAs in DICER mutant cells line displaying a hypomorphic phenotype (Cummins JM, 2006) 
will elucidate the DICER involvement in their processing.  
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